Correlation of expression of enhancer of zeste homolog 2 with the survival outcome in patients with metastatic breast cancer using primary and paired metastatic lesions.
E23227 Background: Enhancer of zeste homolog 2 (EZH2), a Polycomb group protein, has been linked to aggressive breast cancer. Few reports have examined EZH2 expression in metastatic lesions of breast cancer patients. Therefore, the purpose of this study was to investigate the clinicopathological significance of EZH2 expression in metastatic breast cancers (MBCs). Methods: We retrospectively studied the surgical specimens of primary breast cancer (PBC) tumors and their corresponding metastatic lesions from patients (n= 96) who underwent surgery for the PBC tumor between December 1977 and March 2013. Tissue microarrays (TMAs) and whole tissue sections were constructed, using primary and metastatic lesions, and stained with antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and EZH2. We examined the correlations between ER, PR, HER2, Ki-67, and EZH2 expression, and the clinicopathological characteristics and outcome measures of the patients. Results: Compared to primary lesions, metastatic lesions exhibited significantly higher levels of expression of Ki-67 (75.0% vs. 42.7%, P= 0.01) and EZH2 (71.9% vs. 56.3%, P< 0.0001). Ki-67 expression was significantly highly correlated with EZH2 expression in primary lesions and metastatic lesions. Patients expressing high levels of EZH2 in primary lesions were not associated with poorer overall survival (OS) outcomes after recurrence than patients expressing low levels of EZH2 in primary lesions (P = 0.096), whether patients expressing high levels of EZH2 in metastatic lesions were associated with significantly than patients expressing low levels of EZH2 (P = 0.014). High levels of EZH2 expression in metastatic lesions were independently associated with poorer OS outcomes after recurrence. Conclusions: We show that high EZH2 expression levels in metastatic lesions are independently more associated with poorer OS outcomes after recurrence than primary lesions.